Safety of an ultra-rush subcutaneous immunotherapy using an infusion pump in real-life
Objective: To assess the safety of an ultra-rapid schedule of up-dosing phase of subcutaneous immunotherapy (SCIT) using an infusion pump. Methods: We selected in real-life, 60 patients with allergic rhinitis and/or asthma who were sensitized to pets (cat or dog). They received SCIT with Alutard® e...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Colegio Mexicano de Inmunología Clínica y Alergia, A.C.
2018-06-01
|
| Series: | Revista Alergia México |
| Subjects: | |
| Online Access: | http://revistaalergia.mx/ojs/index.php/ram/article/view/467 |
| _version_ | 1797709670978158592 |
|---|---|
| author | Silvia Uriarte Joaquín Sastre |
| author_facet | Silvia Uriarte Joaquín Sastre |
| author_sort | Silvia Uriarte |
| collection | DOAJ |
| description | Objective: To assess the safety of an ultra-rapid schedule of up-dosing phase of subcutaneous immunotherapy (SCIT) using an infusion pump.
Methods: We selected in real-life, 60 patients with allergic rhinitis and/or asthma who were sensitized to pets (cat or dog). They received SCIT with Alutard® extract (ALK-Abelló, Spain) maintenance vial. A portable infusion pump (IP) (Infusa T®, Medis, Italy) was used for subcutaneous administration of the immunotherapy. The infusion lasted 4-hours in the same day. Adverse reactions were monitored.
Results: Sixty doses were administered. Immunotherapy-related adverse reactions (ARs) were reported in 15 patients. By doses, 5 % were local reactions (LRs) and 21.6 % systemic reactions (SRs). All LRs were delayed. Of the SRs, 46.2 % were immediate while 53.8 % delayed SRs. Symptoms associated with SRs were rhinitis (61.5 %), urticaria (38.5 %), conjunctivitis (30.8 %). The most of SRs were grade I (92.3 %) and were treated rapidly.
Conclusion: The up-dosing phase of subcutaneous immunotherapy (SCIT) using an infusion pump in an ultra-rapid schedule could be considered a form of SCIT’s administration. Despite the possible adverse reactions, which in our study were mild reactions. |
| first_indexed | 2024-03-12T06:41:06Z |
| format | Article |
| id | doaj.art-605a73f6679c402888385dfe08d25513 |
| institution | Directory Open Access Journal |
| issn | 0002-5151 2448-9190 |
| language | English |
| last_indexed | 2024-03-12T06:41:06Z |
| publishDate | 2018-06-01 |
| publisher | Colegio Mexicano de Inmunología Clínica y Alergia, A.C. |
| record_format | Article |
| series | Revista Alergia México |
| spelling | doaj.art-605a73f6679c402888385dfe08d255132023-09-03T01:02:21ZengColegio Mexicano de Inmunología Clínica y Alergia, A.C.Revista Alergia México0002-51512448-91902018-06-0165 suppl 184307Safety of an ultra-rush subcutaneous immunotherapy using an infusion pump in real-lifeSilvia Uriarte0Joaquín Sastre1Fundación Jiménez Díaz, Departamento de Alergia, MadridFundación Jiménez Díaz, Departamento de Alergia, MadridObjective: To assess the safety of an ultra-rapid schedule of up-dosing phase of subcutaneous immunotherapy (SCIT) using an infusion pump. Methods: We selected in real-life, 60 patients with allergic rhinitis and/or asthma who were sensitized to pets (cat or dog). They received SCIT with Alutard® extract (ALK-Abelló, Spain) maintenance vial. A portable infusion pump (IP) (Infusa T®, Medis, Italy) was used for subcutaneous administration of the immunotherapy. The infusion lasted 4-hours in the same day. Adverse reactions were monitored. Results: Sixty doses were administered. Immunotherapy-related adverse reactions (ARs) were reported in 15 patients. By doses, 5 % were local reactions (LRs) and 21.6 % systemic reactions (SRs). All LRs were delayed. Of the SRs, 46.2 % were immediate while 53.8 % delayed SRs. Symptoms associated with SRs were rhinitis (61.5 %), urticaria (38.5 %), conjunctivitis (30.8 %). The most of SRs were grade I (92.3 %) and were treated rapidly. Conclusion: The up-dosing phase of subcutaneous immunotherapy (SCIT) using an infusion pump in an ultra-rapid schedule could be considered a form of SCIT’s administration. Despite the possible adverse reactions, which in our study were mild reactions.http://revistaalergia.mx/ojs/index.php/ram/article/view/467subcutaneous immunotherapyinfusion pumpallergic rhinitisasthmapets |
| spellingShingle | Silvia Uriarte Joaquín Sastre Safety of an ultra-rush subcutaneous immunotherapy using an infusion pump in real-life Revista Alergia México subcutaneous immunotherapy infusion pump allergic rhinitis asthma pets |
| title | Safety of an ultra-rush subcutaneous immunotherapy using an infusion pump in real-life |
| title_full | Safety of an ultra-rush subcutaneous immunotherapy using an infusion pump in real-life |
| title_fullStr | Safety of an ultra-rush subcutaneous immunotherapy using an infusion pump in real-life |
| title_full_unstemmed | Safety of an ultra-rush subcutaneous immunotherapy using an infusion pump in real-life |
| title_short | Safety of an ultra-rush subcutaneous immunotherapy using an infusion pump in real-life |
| title_sort | safety of an ultra rush subcutaneous immunotherapy using an infusion pump in real life |
| topic | subcutaneous immunotherapy infusion pump allergic rhinitis asthma pets |
| url | http://revistaalergia.mx/ojs/index.php/ram/article/view/467 |
| work_keys_str_mv | AT silviauriarte safetyofanultrarushsubcutaneousimmunotherapyusinganinfusionpumpinreallife AT joaquinsastre safetyofanultrarushsubcutaneousimmunotherapyusinganinfusionpumpinreallife |